BioWorld® - Medical Device Daily

More documents

Recommendations

Info

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information Advance into Markets for Generic Bio Drugs in Industrialized Countries -Advance into markets in industrialized countries through marketing alliances -Establish local corporations in strategically important areas Firm Up our Position as a Market Leader in the Domestic Market -Continue development of advanced marketing techniques -Focus on the development of products meeting our customers’ specific needs -Strengthen our licensing activities AGREEMENTS: Name Products Content of Agreement Date Aeterna anti-cancer drug in-licensing agreement 2003 Anadys hepatitis B treatment out-licensing and 2004 Pharmaceuticals joint development Inc. agreement Biogen Idec Inc. psoriasis treatment in-licensing agreement 2004 BioPartners sustained-release out-licensing and 2001 human growth hormone joint development agreement BioPartners genetically-engineered joint development 1997 products and marketing agreement DepoMed diabetes treatment in-licensing agreement 2004 Eximias liver cancer treatment in-licensing agreement 2002 GlaxoSmithKline plc new quinolone antibiotic licensing agreement 1997 KYORIN development, licensing agreement 2005 Pharmaceutical manufacturing and Co. Ltd. sales of KRP-197 in Korea Oscient quinolone antibiotics out-licensing 2002 Pharmaceuticals agreement Sinovac Biotech hepatitis B vaccine in distribution 3/06 Ltd. China agreement Sinovac Biotech hepatitis A vaccine, letter of intent 5/05 Ltd. hepatitis B vaccine, combined hep A and hep B vaccine, avian flu vaccine Yamanouchi (now treatments for obesity, R&D collaboration 2001 Astellas Pharma Inc.) hyperlipidaemia RESEARCH & DEVELOPMENT: Anti-cancers Anti-infectives QOL (Quality of Life) PRODUCTS ON MARKET: Factive (Quinolone antibiotics) Intermax gamma (Gamma-IFN) Intermax alpha (Alpha-IFN) LG HCD (hepatitis C diagnostic) LG HBs Ag Elisa (hepatitis B diagnostic) LG Anti-HBs Elisa (hepatitis B diagnostic) LG HCD confirm (hepatitis C diagnostic) Euvax B (hepatitis B vaccine) Eutropin (hGH) Leucogen (GM-CSF) IFN-a Hyruan (Hyaluronic acid) HCD Copyright ©2006 AHC Media ® 222
BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information HBD EPO BGH Ivermectin Ceftiofur PRODUCTS IN DEVELOPMENT: Name Status NEW CHEMICAL ENTITIES: LB 80380 for hepatitis B in Phase II clinicals LB 84451 for HCV, NASH in Phase I clinicals LB 53280 for obesity in preclinicals LC15-0133 for Type II diabetes in preclinicals Thrombin Inh - DVT, AF in preclinicals HCV inhibitor for hepatitis C completed discovery LGC (Laboratory of the Government Chemist) Queens Road Teddington TW11 0LY, UK Phone: +44 (0) 20 8943 7000; Fax: +44 (0)20 8943 2767 Web: www.lgc.co.uk E-mail: info@lgc.co.uk KEY PERSONNEL: Ian Kent; Chairman Dr. Nigel Law; CEO Dr. Paul Debenham; Director, Life Sciences Dr. Angela Gallop; Director, LGC Forensics EMPLOYEES: 1,000+ employees HISTORY: Founded in 1843 LGC (Holdings) Ltd. is formed (2/93) LGC (Holdings) Ltd. acquired Laboratory of the Government Chemist (4/96) Acquired Pipeline Developments Ltd. (1997) Acquired University Diagnostics Ltd. (1997) Acquired ICI's Runcorn analytical unit (1998) Formed GeneSolve, a joint venture with Dundee University (1999) Acquired the Promochem Group of Companies (2001) Sold Pipeline Developments Ltd. (2002) Acquired Forensic Alliance Ltd. (9/05) Acquired Agowa (1/06) FACILITIES: Locations in France, Germany, Spain, Sweden, the U.K., Italy and Poland Distribution office in India STOCK-FINANCIAL HISTORY: Privately held BUSINESS STRATEGY: Vision: Be an international business, recognised for setting standards in analytical science and providing best value products, services and solutions To meet its vision, the company will: increase turnover by 15 percent year on year with profit at or above 10 percent of sales, and achieve 25% of its turnover from outside the U.K. AGREEMENTS: Name Products Content of Agreement Date King’s College pharmacogenetic exclusive licensing 11/05 London screening service that will predict if a patient with schizophrenia will respond positively to clozapine agreement Copyright ©2006 AHC Media ® 223
Page 1 and 2:
BioWorld ® INDUSTRIAL BIOTECHNOLGY
Page 3 and 4:
BioWorld Industrial Biotechnology S
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Applera Corp. BioWorld Industrial B
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
CABI BioWorld Industrial Biotechnol
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Cargill Inc. BioWorld Industrial Bi
Page 109 and 110:
Ceapro Inc. BioWorld Industrial Bio
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Digene Corp. BioWorld Industrial Bi
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
EvoGenix Ltd. BioWorld Industrial B
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Galderma SA BioWorld Industrial Bio
Page 169 and 170:
Page 171 and 172: BioWorld Industrial Biotechnology S
Page 185 and 186: Hercules Inc. BioWorld Industrial B
Page 197 and 198: Iogen Corp. BioWorld Industrial Bio
Page 217 and 218: Lake States BioWorld Industrial Bio
Page 221: BioWorld Industrial Biotechnology S
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Paprican BioWorld Industrial Biotec
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Primm S.R.L. BioWorld Industrial Bi
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Prokaria ehf BioWorld Industrial Bi
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Recordati SpA BioWorld Industrial B
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Symbio BioWorld Industrial Biotechn
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
UVP Inc. BioWorld Industrial Biotec
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
YMC Co. Ltd. BioWorld Industrial Bi
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
show all

BioWorld® - Medical Device Daily

Create successful ePaper yourself

Delete template?

Save as template?